Eagle Patent-Cliff Exposure & CMS Drug Spending Portfolio

Eagle (US): 3 reconciled FDA prescription therapies, $21.1M 2024 CMS Part D & Medicaid spend, and $4,453 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies3
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE Date2031-01-01
2024 CMS Total Public Spend$21.1M
2024 Medicare Part D Spend$1.5M
2024 Medicaid Spend$19.6M
California HCAI SB 17 FilingsSpecialty launch notice ($4,453 intro WAC)